Apo-amitriptyline: Affected Lots May Exceed The Interim Acceptable Intake Limit For Nnort
Apo-Amitriptyline tablets are being recalled across Canada because certain affected batches may contain higher levels of an impurity called NNORT than are considered safe for regular use. The impurity could pose a health risk if the affected product is taken over time. This recall affects all patients in Canada who are currently using Apo-Amitriptyline.
- Product
- Apo-Amitriptyline
- Reason
- Product safety
- Classification
- Class I
- Category
- drug recall
- Country
- Canada
- Agency
- HC-DRUGS
- Recall date
- 2024-10-17
- Status
- Ongoing
- Distribution
- Canada-wide
Official recall notice from HC-DRUGS
Recall details on Nibble Recalls: https://trynibble.app/recalls/ad5a6443-39d9-481b-bd9e-1231999c0878